Display options
Cite
Solgi G, Sabouri Ghannad M, Khalilian A, et al. Molecular epidemiology of hepatitis C virus and its relation with persistence or clearance of infection in Hamadan, West-Iran. Iran J Microbiol. 2015;7(2):109-17
Solgi, G., Sabouri Ghannad, M., Khalilian, A., Majlesi, A., & Hajiloo, M. (2015). Molecular epidemiology of hepatitis C virus and its relation with persistence or clearance of infection in Hamadan, West-Iran. Iranian journal of microbiology, 7(2), 109-17.
Solgi, Ghasem, et al. "Molecular epidemiology of hepatitis C virus and its relation with persistence or clearance of infection in Hamadan, West-Iran." Iranian journal of microbiology vol. 7,2 (2015): 109-17.
Solgi G, Sabouri Ghannad M, Khalilian A, Majlesi A, Hajiloo M. Molecular epidemiology of hepatitis C virus and its relation with persistence or clearance of infection in Hamadan, West-Iran. Iran J Microbiol. 2015 Apr;7(2):109-17. PMID: 26622972; PMCID: PMC4662778.
Copy Download .nbib Format: NLM
Share it on

Iran J Microbiol. 2015 Apr;7(2):109-17.

Molecular epidemiology of hepatitis C virus and its relation with persistence or clearance of infection in Hamadan, West-Iran.

Iranian journal of microbiology

Ghasem Solgi, Masoud Sabouri Ghannad, Alireza Khalilian, Amir Majlesi, Mehrdad Hajiloo

Affiliations

  1. Immunology Department, Medical School, Hamadan University of Medical Sciences, Hamadan, IRAN.
  2. Department of Microbiology, Medical school, Hamadan University of Medical Sciences, Hamadan, IRAN.
  3. Department of Gastroenterology, Medical School, Hamadan University of Medical Sciences, Hamadan, IRAN.

PMID: 26622972 PMCID: PMC4662778

Abstract

BACKGROUND AND OBJECTIVES: Hepatitis C Virus genotyping appears to be vital for predicting the response to antiviral therapy. The present study aimed to analyze the HCV genotypes in relation to persistence or clearance of the virus in residents of Hamadan Province, West-Iran.

MATERIAL AND METHODS: A total of 1159 recorded questionnaires of HCV infected people were evaluated in this prospective study. Several parameters including HCV genotypes, anti-HCV antibodies, viral load, drug treatment, response to therapy and amount of ALT and AST were analyzed.

RESULTS: HCV genotyping in 637 samples revealed a predominance of type 1a (52.1%) followed by 3a (42.4%), type 1b (2.7%) and type 2 (0.2%) respectively. Mixed genotypes (3a-1a) were detected in 0.9%, and 1.7% had untypable genotype. High frequency of genotypes 1a and 3a were observed in drug-resistant (group-a) and drug-sensitive (group-b) patients respectively (P<0.0001). Additionally, duration of drug treatment was significantly higher in group-a than group-b (P<0.0001). During follow-up period, 92 cases showed spontaneous clearance of HCV infection and more importantly 86 of 92 cases were positive for anti-HCV antibodies compared with 59 of 455 antibody positive cases with treatment-induced clearance of HCV infection (P<0.0001).

CONCLUSION: HCV genotyping and also antibody screening could be useful for proper therapeutic intervention in HCV infected subjects.

Keywords: Antibody; Epidemiology; Genotype; HCV

References

  1. Ernst Schering Res Found Workshop. 2006;(55):99-120 - PubMed
  2. J Med Virol. 2014 Aug;86(8):1342-9 - PubMed
  3. Hepatology. 2001 Jan;33(1):224-30 - PubMed
  4. Dig Dis Sci. 2011 Mar;56(3):880-8 - PubMed
  5. J Med Virol. 2004 Oct;74(2):246-52 - PubMed
  6. Gastroenterology. 2006 Apr;130(4):1086-97 - PubMed
  7. Liver. 1996 Dec;16(6):353-7 - PubMed
  8. Nihon Rinsho. 1994 Jul;52(7):1734-7 - PubMed
  9. Jundishapur J Microbiol. 2015 Feb 20;8(2):e16722 - PubMed
  10. Int J Infect Dis. 2002 Dec;6(4):272-6 - PubMed
  11. J Med Virol. 2011 Aug;83(8):1338-44 - PubMed
  12. Virol J. 2011 Sep 08;8:433 - PubMed
  13. Intervirology. 2013;56(3):201-5 - PubMed
  14. Int J Infect Dis. 2002 Sep;6(3):228-32 - PubMed
  15. Expert Rev Anti Infect Ther. 2011 Sep;9(9):747-59 - PubMed
  16. Can J Gastroenterol. 2010 Oct;24(10 ):597-602 - PubMed
  17. Liver Int. 2005 Dec;25(6):1122-7 - PubMed
  18. Eur Rev Med Pharmacol Sci. 2010 Oct;14(10):861-4 - PubMed
  19. Lancet. 1999 Dec 18-25;354(9196):2119-24 - PubMed
  20. Comp Hepatol. 2006 Oct 02;5:4 - PubMed
  21. Int J Immunogenet. 2008 Feb;35(1):37-43 - PubMed
  22. Infection. 2003 Mar;31(2):92-7 - PubMed
  23. Hepatol Res. 2007 Feb;37(2):101-3 - PubMed
  24. Hepat Mon. 2013 Jan;13(1):e7991 - PubMed
  25. J Gastroenterol Hepatol. 2002 Dec;17 Suppl:S468-70 - PubMed

Publication Types